A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCCs)
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 15 Aug 2017 Status changed from active, no longer recruiting to completed.
- 17 Mar 2016 Planned End Date changed from 1 Nov 2015 to 1 Nov 2017, as reported by ClinicalTrials.gov.
- 17 Mar 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017, as reported by ClinicalTrials.gov.